ZYNYZ retifanlimab
瑞弗利单抗
Drug Class
PD-1 antagonist monoclonal antibodyPD-1 拮抗性单克隆抗体
Mechanism
Binds to PD-1 on immune cells, preventing ligand binding (PD-L1 and PD-L2) and restoring T-cell activation and proliferation.特异性结合免疫细胞表面的PD-1受体，阻止其与配体（PD-L1和PD-L2）结合，从而恢复T细胞的活化和增殖并提高抗肿瘤免疫反应。
Approved Indication
Metastatic or recurrent locally advanced Merkel cell carcinoma, per its FDA approval.根据美国FDA批准，适用于治疗转移性或复发性局部晚期默克尔细胞癌（MCC）。
What This Means For Patients
ZYNYZ is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.ZYNYZ（瑞弗利单抗）目前未通过中国大陆零售药房渠道销售。优健云可协助安排购买渠道，药品由香港采购发货；如有需要，可协调来华后的临床用药支持。具体供应及患者适用性以医疗预检评估为准。
Regulatory Approvals
- FDA — Approved (2023) — Sources
Pivotal Clinical Evidence
- POD1UM-201 — Grignani et al., J Immunother Cancer 2025 (NCT03599713) — Sources